MEDICAMEN BIOTECH
|
MEDICAMEN BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.47 | 11.64 | 12.19 | 9.93 | 10.88 |
| CEPS(Rs) | 13.05 | 16.67 | 16.92 | 11.99 | 12.93 |
| DPS(Rs) | - | - | 1.00 | 1.00 | 0.50 |
| Book NAV/Share(Rs) | 157.52 | 145.25 | 113.56 | 103.33 | 97.55 |
| Tax Rate(%) | 27.39 | 13.59 | 17.67 | 26.01 | 26.08 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.11 | 17.28 | 20.86 | 17.45 | 15.52 |
| EBIT Margin(%) | 10.46 | 14.51 | 17.36 | 15.89 | 15.07 |
| Pre Tax Margin(%) | 7.29 | 12.10 | 15.67 | 14.54 | 14.33 |
| PAT Margin (%) | 5.29 | 10.46 | 12.90 | 10.76 | 10.59 |
| Cash Profit Margin (%) | 9.25 | 14.98 | 17.90 | 13.00 | 12.58 |
| Performance Ratios | |||||
| ROA(%) | 3.34 | 5.87 | 7.11 | 6.46 | 8.36 |
| ROE(%) | 4.94 | 9.13 | 11.25 | 9.89 | 12.94 |
| ROCE(%) | 8.46 | 10.85 | 12.94 | 12.99 | 16.54 |
| Asset Turnover(x) | 0.63 | 0.56 | 0.55 | 0.60 | 0.79 |
| Sales/Fixed Asset(x) | 1.34 | 1.11 | 0.96 | 1.30 | 2.41 |
| Working Capital/Sales(x) | 2.39 | 1.74 | 2.29 | 2.64 | 2.63 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.74 | 0.90 | 1.04 | 0.77 | 0.42 |
| Receivable days | 122.66 | 166.45 | 183.01 | 165.97 | 135.71 |
| Inventory Days | 106.29 | 93.37 | 50.92 | 35.88 | 46.85 |
| Payable days | 215.82 | 311.49 | 316.67 | 253.69 | 189.02 |
| Valuation Parameters | |||||
| PER(x) | 51.31 | 56.31 | 52.79 | 53.78 | 16.61 |
| PCE(x) | 29.37 | 39.31 | 38.05 | 44.53 | 13.98 |
| Price/Book(x) | 2.43 | 4.51 | 5.67 | 5.17 | 1.85 |
| Yield(%) | - | - | 0.16 | 0.19 | 0.28 |
| EV/Net Sales(x) | 2.81 | 5.92 | 7.00 | 5.92 | 1.83 |
| EV/Core EBITDA(x) | 19.48 | 31.13 | 31.32 | 32.67 | 10.70 |
| EV/EBIT(x) | 26.85 | 40.82 | 40.35 | 37.27 | 12.12 |
| EV/CE(x) | 2.18 | 3.93 | 3.59 | 3.44 | 1.26 |
| M Cap / Sales | 2.72 | 5.89 | 6.81 | 5.79 | 1.76 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 27.29 | 22.02 | 2.42 | -10.19 | 2.36 |
| Core EBITDA Growth(%) | -3.59 | 3.86 | 26.35 | -4.60 | 1.38 |
| EBIT Growth(%) | -8.27 | 2.00 | 11.90 | -5.32 | 0.04 |
| PAT Growth(%) | -35.54 | -1.14 | 22.82 | -8.74 | 10.52 |
| EPS Growth(%) | -35.86 | -4.53 | 22.82 | -8.74 | 5.85 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.16 | 0.14 | 0.19 | 0.15 | 0.10 |
| Current Ratio(x) | 1.89 | 1.98 | 1.69 | 1.80 | 1.84 |
| Quick Ratio(x) | 1.31 | 1.50 | 1.36 | 1.70 | 1.54 |
| Interest Cover(x) | 3.31 | 6.03 | 10.32 | 11.85 | 20.30 |
| Total Debt/Mcap(x) | 0.06 | 0.03 | 0.03 | 0.03 | 0.05 |
Compare Financial Ratios of peers of MEDICAMEN BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MEDICAMEN BIOTECH | ₹584.6 Cr | 2.9% | -12.1% | -14.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,228.0 Cr | -2.4% | -7.2% | 27.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹148,023.0 Cr | 0% | -9.2% | 61.5% | Stock Analytics | |
| CIPLA | ₹119,474.0 Cr | 6% | -3.8% | 10.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,599.0 Cr | 1.7% | -11.4% | 2.2% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,604.7 Cr | 5.2% | -2.1% | 26.1% | Stock Analytics | |
MEDICAMEN BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MEDICAMEN BIOTECH | 2.9% |
-12.1% |
-14.5% |
| SENSEX | 1.7% |
-1.3% |
7.7% |
You may also like the below Video Courses
